Summary Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. The main objective ... Individual.com, 5 days ago
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future - European Heart Journal, 1 week ago
PCSK9 antibodies safe and effective in treating dyslipidemia - 2 Minute Medicine, 3 weeks ago
3 images for "kexin"
China's Fan Kexin continues to set the pace in the early part of the new World Cup short track speed skating season after winning the 500m final in Montreal. . View photo Kexin Fan, February 2012 The Olympic 1000m silver medallist climbed ...Yahoo! UK and Ireland Eurosport, 1 week ago Two World silvers for Christie Sky Sports, 1 month ago
Thomson Reuters is the world's largest international multimedia news agency, providing investing news , world news , business news , technology news , headline news, small business news, news alerts, personal finance , stock market , and mutual ...Reuters UK, 2 months ago
[Photo/IC] CHANGCHUN - Each morning at 8 am, Wang Kexin puts on his helmet and leg guards and hops on a motorcycle to begin his workday. The 31-year-old goes door to door through villages in Maolin township in Northeast China's Jilin province to ...CHINAdaily Europe, 1 month ago Rural couriers ride wave of e-commerce expansion China Economic Net, 1 month ago ALIBABA : China's rural couriers ride wave of e-commerce expansion 4 Traders, 1 month ago Shopping online proves a boon for rural residents Shanghai Daily, 4 weeks ago
by Liuna Geng, Jingke Xu, Lijuan Ye, Wenjun Zhou, Kexin Zhou The influence of environmental attitudes on environmental behaviors has long been discussed. However, few studies have addressed the foundation of such attitudes. In the present study, we ...Plosone.org, 6 days ago
Letter From Le May and Cariou Regarding Article, "Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent
Letter From Le May and Cariou Regarding Article, Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein ReceptorDependent and ...Circulation: Cardiovascular Interventions, 2 weeks ago Response to Letter Regarding Article, "Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms" Circulation: Cardiovascular Interventions, 2 weeks ago
Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Repatha (evolocumab) recommending approval for use in certain ...PharmaBiz, 2 hours ago Amgen Receives Positive Opinion For Use Of Repatha (Evolocumab) For The Treatment Of High Cholesterol BioSpace, 2 days ago Amgen (AMGN) First To Win EU Support For New Kind Of Cholesterol Drug 5/22/2015 ClinicSpace, 3 days ago Pending EC decision: Repatha, evolocumab, Opinion date: 21-May-2015 European Medicines Agency, 3 days ago
Amgen (AMGN), Sanofi (SAN.PA) in Race to Get European Green light for Anti-Cholesterol Drugs 5/21/2015
May 20, 2015 By Alex Keown , BioSpace.com Breaking News Staff LONDON Amgen ( AMGN )'s cholesterol drug Repatha could be recommended for approval in Europe later this week, which would give the California-based Amgen a leg up over rival ...ClinicSpace, 2 days ago Amgen Beats Sanofi to Market with EU Hurdle for Anti-Cholesterol Drug BioSpace, 2 days ago Amgen (AMGN) Beats Sanofi (SAN.PA) to Market with EU Hurdle for Anti-Cholesterol Drug 5/22/2015 ClinicSpace, 2 days ago Amgen, Sanofi in Race to Get European Green light for Anti-Cholesterol Drugs BioSpace, 4 days ago
- The global treatment market for dyslipidemia will more than double in value from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, representing a Compound Annual Growth Rate (CAGR) of 9.4%, according to research and consulting firm ...PharmaceuticalProcessing, 4 days ago Dyslipidemia treatment market value will approach $38 billion by 2023, says GlobalData European Pharmaceutical Review, 4 days ago
Graeme J Hankey , professor of neurology 1 , consultant neurologist 2 , research affiliate and honorary senior research fellow 3 1 School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute of Medical Research, ...British Medical Journal, 6 days ago
on your WebpageAdd Widget >Get your members hooked!